Identification of potential COVID-19 main protease inhibitors using structure-based pharmacophore approach, molecular docking and repurposing studies by SAFA DAOUD et al.
163
Acta Pharm. 71 (2021) 163–174 Preliminary communication 
https://doi.org/10.2478/acph-2021-0016
Identification of potential COVID-19 main protease inhibitors 
using structure-based pharmacophore approach, molecular 
docking and repurposing studies
The current outbreak of novel coronavirus (COVID-19) infec-
tions urges the need to identify potential therapeutic agents. 
Therefore, the repurposing of FDA-approved drugs against 
today’s diseases involves the use of de-risked compounds with 
potentially lower costs and shorter development timelines. In 
this study, the recently resolved X-ray crystallographic struc-
ture of COVID-19 main protease (Mpro) was used to generate 
a pharmacophore model and to conduct a docking study to 
capture antiviral drugs as new promising COVID-19 main 
protease inhibitors. The developed pharmacophore success-
fully captured five FDA-approved antiviral drugs (lopinavir, 
remdesivir, ritonavir, saquinavir and raltegravir). The five drugs 
were successfully docked into the binding site of COVID-19 
Mpro and showed several specific binding interactions that 
were comparable to those tying the co-crystallized inhibitor 
X77 inside the binding site of COVID-19 Mpro. Three of the 
captured drugs namely, remdesivir, lopinavir and ritonavir, were 
reported to have promising results in COVID-19 treatment and 
therefore increases the confidence in our results. Our findings 
suggest an additional possible mechanism of action for rem-
desivir as an antiviral drug inhibiting COVID-19 Mpro. Additio-
nally, a combination of structure-based pharmacophore modeling 
with a docking study is expected to facilitate the discovery of 
novel COVID-19 Mpro inhibitors.
Keywords: COVID-19, main protease, pharmacophore, struc-
ture-based modeling, docking study, remdesivir, repurposing 
The World Health Organization (WHO) was informed on December 2019 about a clus-
ter of unexplained severe pneumonia cases in Wuhan, China, known later to be caused by 
a novel beta coronavirus (1). Coronavirus is an enveloped, positive-sense and single- 
-stranded RNA virus from the genus Betacoronavirus that is distributed in birds, humans 
and other mammals (2, 3). WHO has named this novel coronavirus disease as COVID-19 
(4). A novel coronavirus has resulted in an ongoing outbreak of viral pneumonia all over 
the world, forcing the WHO to declare that the outbreak of this deadly and fast-spreading 
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infectious pneumonia represents a global health emergency (5). Despite rigorous global 
containment and quarantine efforts, the incidence of COVID-19 continues to rise. Accord-
ing to WHO official records, as of May 31st, 2020, there have been 5,934,936 infected people 
globally and 367,166 confirmed deaths in 216 countries, areas or territories with reported 
cases of the disease (6).
At present, there are no specific effective antiviral drugs or vaccines against COVID-19 
infection. Current treatments are mainly directed towards supporting the symptomatic 
and respiratory conditions. Therefore, there is an urgent need to new studies and appro-
aches that facilitate the identification of effective therapy that fight such life-threatening 
virus (7). Under the current global COVID-19 pandemic, drug repurposing represents an 
attractive and promising approach to identify possible treatment strategies using already 
FDA-approved marketed drugs (8). Obviously, the repurposing of such drugs against 
 today’s diseases involves the use of de-risked compounds with potentially lower overall 
costs and shorter development timelines (9, 10). Computer-aided drug design techniques 
represent a very efficient approach to provide promising results in drug discovery. Structure- 
-based pharmacophore approach has proven to be useful for supporting in silico hit discovery, 
hit-to-lead expansion, and lead optimization (11, 12). The protein-ligand  complex based 
approach is specialized to gain insights into ligand-protein interactions and to  identify the 
essential pharmacophore features necessary for optimal interaction and biological activity 
(13). Furthermore, structure-based pharmacophore models obtained using single ligand- 
-target structures have proven their worth as an alternative to the traditional approaches. 
This is particularly evident by their role in the virtual screening process, where they have 
taken center stage in many studies (11, 14).
The COVID-19 virus encodes two polyproteins that are crucial for viral replication 
and transcription; pp1a and pp1ab. COVID-19 virus’ main protease (Mpro), also referred 
to as 3-chymotrypsin-like protease (3C-like protease), plays a pivotal role in releasing the 
functional polypeptides from the polyproteins (15). Therefore, Mpro represents a new 
 attractive drug target for the discovery of potential therapeutics against COVID-19. 
In this study, we aim to apply a structure-based pharmacophore drug design  approach 
combined with a docking study as a quick approach to identify promising FDA-approved 
antiviral drugs that can target COVID-19 virus main protease.
METHODS
Pharmacophore generation 
Pharmacophore generation and docking studies were performed using DiscoveryStu-
dio 2.5.5 from Accelrys Software (BIOVIA, USA). The 3D coordinates of COVID-19 Mpro 
complexed with inhibitor, X77, were downloaded from the Protein Data Bank (PDB code: 
6W63, 2.10 Å) (https://www.rcsb.org/). Hydrogen atoms were added to the proteins utilizing 
DiscoveryStudio 2.5.5 templates for protein residues and the water molecules were kept in 
the protein structure. The protein-inhibitor complex was carefully explored to identify the 
intermolecular interactions; only those interactions located within a maximum of 3 Å 
 distance were considered. A structure-based pharmacophore approach that relies on these 
interactions was conducted and manual pharmacophore generation was carried on. 
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Screening FDA-approved antiviral drugs
Based on a literature survey, 36 FDA-approved antiviral drugs were used in this study 
including abacavir, acyclovir, amprenavir, asunaprevir, atazanavir, boceprevir, daclatas-
vir, danoprevir, darunavir, dolutegravir, efavirenz, entecavir, etravirine, favipiravir, 
fosamprenavir, galidesivir, ganciclovir, grazoprevir, indinavir, lamivudine, lomibuvir, 
lopinavir, nelfinavir, nevirapine, penciclovir, raltegravir, remdesivir, ribavirin, rilpivirine, 
ritonavir, saquinavir, simeprevir, telaprevir, tipranavir, triflurdine and umifenovir. The 
3D structure of each drug was downloaded from the PubChem database (https://pubchem.
ncbi.nlm.nih.gov/) and a list in (SD) format was prepared. 
The prepared list was mapped against our developed pharmacophore employing the 
“Caeser-Flexible ligand pharmacophore mapping” option implemented within CATALYST 
(HYPOGEN module), as an attempt to identify potential COVID-19 protease inhibitors. 
Docking study
COVID-19 Mpro crystal structure (PDB code: 6W63, 2.10 Å) was utilized in subsequent 
docking experiments without energy minimization. Explicit water molecules were kept in 
the binding pocket. The docking experiment was adapted from the team’s previous pub-
lications (16, 17) using the site-feature docking algorithm (LibDock). A sphere of 7.64 Å 
radius based on the co-crystallized ligand was used to define the binding site. LibDock is 
a docking algorithm that positions the generated ligand conformations in the protein  active 
site based on polar and apolar interaction sites (hotspots). It uses standard Catalyst engine 
in DiscoveryStudio 2.5.5 to generate conformations using “best” option (a maximum of 
250 conformers in which each of them not exceeding an energy threshold of 20 kcal mol–1 
from the most stable conformer) with final CHARMm minimization step to optimize the 
docked poses (18, 19). 
Top poses were kept for subsequent scoring where 7 docking-scoring functions were 
employed [Jain (20), LigScore1, LigScore2 (21, 22), PLP1, PLP2 (23), PMF and PMF04 (24, 25)]. 
The docking and scoring settings that had closely reproduced the crystallographic pose of 
the potent inhibitor X77 were selected to carry docking experiments for antiviral drugs 
that were captured by the generated pharmacophore.
RESULTS AND DISCUSSION
The urgent need for treatments during the COVID-19 pandemic makes computer-
aided drug design a very efficient technique to apply, in order to quickly identify promis-
ing drug repurposing candidates, especially after the detailed 3D-structures of various 
key proteins are resolved (26, 27). In this study, COVID-19 Mpro, or 3CL-protease, was used 
to generate a pharmacophore model and to perform a docking experiment to identify po-
tential COVID-19 Mpro inhibitors from the FDA-approved antivirals, and hence, facilitate 
the repurposing of these drugs as potential treatments for COVID-19. The COVID-19 Mpro 
is the main protease used to cleave polyproteins into replication-related proteins and, thus, 
plays a crucial role in mediating viral replication and transcription (15). The 3CL-protease 
structure (PDB code: 6W63) was obtained from the RCSB Protein Data Bank which was 
recently released on March 25th, 2020 (28). It goes without saying that the information 
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about the protein structure from its X-ray crystal structures is a good source to generate 
the structure-based pharmacophore (14).
Initially, the X-ray crystallographic structure of Mpro complexed with the inhibitor 
X77 was carefully inspected to identify the protein-ligand interactions. Fig. 1 shows the 
binding interactions anchoring the potent inhibitor X77 within COVID-19 Mpro binding 
site. Apparently, the co-crystalized inhibitor binds into the binding site via several hydro-
gen bonding, π-stacking and hydrophobic interactions. The potent inhibitor X77 is in-
volved in five hydrogen-bonding interactions connecting its amidic NH with the carbonyl 
of Asn142 via bridging water molecule, the amidic carbonyl with NH of Glu166, the other 
carbonyl with NH of Gly143, imidazole N with Thr26 via two bridging water molecules, 
and the fifth hydrogen bond interaction connects the second imidazole N with NH of 
His41. Additionally, two π-π stacking interactions are noted. First, between the benzene 
ring of the potent inhibitor X77 and the imidazole ring of His41, where the second π-π 
stacking involves inhibitor’s pyridine ring where it sandwiched between the benzene ring 
of Phe140 and the imidazole ring of His172. Furthermore, the projected tert-butyl of X77 
Fig. 1. Detailed view of interactions of different amino acid residues within the binding pocket of 
COVID-19 Mpro with the potent co-crystallized inhibitor X77 (PDB code: 6W63). Hydrogen bonding 
interactions are shown as dotted black lines.
Table I.  Coordinates of the developed COVID-19 main protease pharmacophore
HBA HBA HBA HBA HBD RingArom RingArom Hbic
X –21.494 –19.343 –19.228 –16.85 –22.267 –16.883 –20.274 –21.498
Y 17.268 24.35 25.136 16.203 21.457 20.223 16.561 14.523
Z –34.948 –32.339 –29.25 –25.921 –24.868 –24.4 –26.164 –29.359
HBA – hydrogen bond acceptor, HBD – hydrogen bond donor, RingArom – aromatic rings, Hbic – hydrophobic 
feature
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towards Met165 and Cys44 suggests the existence of mutual hydrophobic interactions that 
anchor this inhibitor within the binding pocket of COVID-19 Mpro.
The former interactions between the potent inhibitor X77 and the binding pocket of 
COVID-19 Mpro were used to guide the manual generation of pharmacophore theory, where 
each interaction is translated into an equivalent feature (Fig. 2). The constructed pharmaco-
phore theory includes eight features: four hydrogen bond acceptors (HBA), one hydrogen 
bond donor (HBD), two aromatic rings (RingArom) and one hydrophobic feature (Hbic) as 
shown in Fig. 3. XYZ coordinates for each feature are represented in Table I. It is well known 
that the selectivity of the pharmacophore is highly dependent on the number of features; 
Fig. 2. Manual generation of the pharmacophore as guided by the interactions of the potent inhibitor 
within the binding pocket of COVID-19 main protease (Fig. 1).
Fig. 3. The generated pharmacophore theory. HBA is shown as vectored green spheres, HBD as vec-
tored pink spheres, Hbic is shown as a blue sphere and RingArom as vectored orange spheres.
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Fig. 4. Mapping of the five captured FDA approved drugs against the developed pharmacophore: a) 
lopinavir, b) remdesivir, c) ritonavir, d) saquinavir and e) raltegravir.
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complex pharmacophores with a high number of features are more selective than simple 
ones with a low number of features (29). The generated pharmacophore herein has eight 
features that will enhance its selectivity and, consequently, restrict the number of captured 
hits and increase the chance of correctly capturing true positive hits.
Based on the developed pharmacophore model, ligand pharmacophore mapping was 
performed using the prepared list of the 36 FDA-approved antiviral drugs to select potential 
drug-candidates. Out of the 36 drugs, our pharmacophore successfully captured five drugs 
namely: lopinavir, remdesivir, ritonavir, saquinavir and raltegravir (supplementary material, 
Fig. S1). Fig. 4 shows how these five drugs mapped against the developed pharmacophore. 
To further increase the confidence of our results, a docking study for the five captured 
antiviral drugs into the catalytic site of COVID-19 Mpro was conducted. Before performing 
a docking study, the docking settings used herein were validated by comparing the crys-
tallographic pose of the potent inhibitor X77 complexed within COVID-19 Mpro with the 
docked pose of the same ligand. The docking settings and the scoring function Ligscore2 
closely reproduced the crystallographic pose of X77 (Fig. 5) with root mean square differ-
ence (RMSD) value of 0.93 Å providing confidence to dock the five captured antiviral drugs 
using the same settings. Interestingly, the five captured antivirals were successfully 
docked inside the binding pockets of COVID-19 Mpro. Fig. 6 shows the binding interac-
tions tying these antiviral drugs within the Mpro binding pocket as proposed by the dock-
ing study. It appears that the antiviral drugs can be involved in several binding inter-
actions within the binding pockets of COVID-19 Mpro (hydrogen bonding, hydrophobic 
and stacking attractions) comparable to the binding interactions tying co-crystallized 
 ligands X77 into this protease, as stated earlier.
The docked pose of lopinavir is involved in four hydrogen bondings with NH of 
Glu166, carbonyl of Leu167 and Asn142 via bridging water molecule and the carboxylate of 
Glu166 via water molecule also. Additionally, π-stacking interactions within the binding 
pocket of Mpro were noticed between one of the benzene rings of lopinavir against the 
amide of Gln189 indicating mutual π-amide stacking interaction. The other benzene ring 
is docked at close proximity to the aromatic side chain of Phe140 while dimethylbenzene 
is sandwiched between Tyr54 and His41 suggesting two mutual π-π stackings (Fig. 6a).
Fig. 5. Comparison between the docked pose of COVID-19 Mpro inhibitor X77 (green) as produced 
by docking simulation and the crystallographic structure of X77 within the COVID-19 Mpro binding 
pocket (red, PDB code: 6W63), RMSD value = 0.93 Å.
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Fig. 6. Detailed view showing the interactions of different amino acid residues within the binding 
pocket of COVID-19 main protease (Mpro) with the docked antiviral drugs: a) lopinavir, b) remdesi-
vir, c) ritonavir, d) saquinavir and e) raltegravir. Hydrogen bonding interactions are shown as dotted 
black lines.
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The docked pose of remdesivir is involved in seven hydrogen bondings with NH of 
His41, carbonyl of Asn142 via water molecule, carbonyl of Glu166, amidic NH2 of Gln189 
and SH of Cys145. Moreover, the benzene ring of remdesivir is docked in close vicinity of 
the aromatic side chains of His163, Phe140 and His172, suggesting mutual π-π stacking, 
where the lipophilic chain of remdesivir is very close to Met49 and Met165 side chains 
indicating the probability of hydrophobic interaction (Fig. 6b).
The docked pose of ritonavir is involved in four hydrogen bondings with amidic NH2 
of Gln189, carbonyl of Glu166, amidic carbonyl of Gln189 and amidic carbonyl of Asn142, 
the last three interactions via bridging water molecules. Furthermore, ritonavir is involved 
in π-π stacking with His41 and hydrophobic interaction with Cys44 and Met49 (Fig. 6c).
Likewise, the docked pose of saquinavir tying itself in Mpro binding pocket through 
six hydrogen bondings with the hydroxyl of Ser144, NH of His163, NH of Glu166, carbonyl 
of Glu166, amidic NH2 of Gln189 and the amidic carbonyl of Asn142 via a water molecule. 
Also, the close proximity to the aromatic ring of His41 and the side chain of Met49 sug-
gesting the probability of π-π stacking and hydrophobic interactions, resp. (Fig. 6d). 
The docked pose of raltegravir is involved in hydrogen bonding interactions with the 
amidic NH2 of Gln189, the carbonyl of Arg188, NH of His172, NH of His41 and the car-
bonyl of Asn142, the latter two interactions via bridging water molecules. Similarly, the 
close proximity to aromatic side chains of His41, His163 and His172 suggesting π-π stack-
ing interactions (Fig. 6e).
The results obtained from the docking study support the outcomes of pharmacophore 
model mapping and confirm that the five antiviral drugs captured by the generated phar-
macophore model could be involved in several binding interactions within the binding 
pockets of COVID-19 Mpro. Most importantly, these interactions are comparable to the 
binding interactions tying the co-crystallized inhibitor X77 into the Mpro binding site.
Interestingly, three of the captured drugs, lopinavir, remdesivir and ritonavir, have 
been clinically tested as a potential treatment for COVID-19 (30). Remdesivir is a nucleotide 
analog inhibitor of the Ebola virus RNA-dependent RNA polymerase (31) and has shown 
promising results in the treatment of COVID-19 infection (32). The ability of the developed 
pharmacophore herein to capture remdesivir (Fig. 4b) and the numerous binding inter-
actions that anchor remdesivir within the binding site of COVID-19 Mpro (Fig. 6b) suggest 
that the potential ability of remdesvir to inhibit COVID-19 Mpro might contribute to its 
reported useful clinical effect in COVID-19 cases. Our results provide an additional pos-
sible mechanism of action for remdesivir as an antiviral drug. Needless to say, dual inhi-
bitors are much more efficient and have more favorable outcomes (33). Lopinavir and 
 ritonavir, HIV protease inhibitors approved for acquired immune deficiency syndrome 
(AIDS) treatment in several countries (34), were both captured by the pharmacophore 
(Figs. 4a,c) and successfully docked in Mpro binding sites (Figs. 6a,c). Although, currently 
there is no strong evidence for the efficacy of lopinavir/ritonavir in the treatment of 
 COVID-19 (35), Cao et al. (36) have reported that hospitalized patients with severe COVID-19 
who received lopinavir/ritonavir had slightly lower 28-day mortality rate. The agreement 
of our findings with the results from reported clinical trials proves the validity of the 
 approach followed in this study. The remaining two captured antiviral drugs, saquinavir 
and raltegravir, showed several interactions within COVID-19 Mpro suggesting that these 
two drugs might act as promising COVID-19 main protease (Mpro) inhibitors. However, 
to the best of our knowledge, until now there are no clinical studies regarding the effect-
iveness of these two drugs as COVID-19 treatments. 
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CONCLUSIONS
A simple structure-based approach was conducted to develop a pharmacophore  model 
for COVID-19 main protease (Mpro) binding site. Five antiviral drugs were captured by the 
developed pharmacophore and docked inside the binding site of COVID-19 Mpro. The five 
antiviral drugs (lopinavir, remdesivir, ritonavir, saquinavir and raltegravir) showed spe-
cific binding interactions within Mpro binding pocket that were comparable to those tying 
the co-crystallized inhibitor X77. Our results agreed with clinical trials where three of the 
captured drugs, lopinavir, remdesivir and ritonavir, showed promising results in COVID-19 
treatment. The remaining two drugs, saquinavir and raltegravir, are highly recommended 
to be taken into consideration while treating COVID-19. The strategy followed herein by 
combining structure-based pharmacophore modeling with a docking study is expected to 
facilitate the discovery of novel COVID-19 Mpro inhibitors by exploring different data-
bases, including natural products or designing novel inhibitors based on the developed 
pharmacophore. In vitro bioassay using recombinant COVID-19 main protease was not 
conducted for the five captured hits due to time constraints with regards to shipment of 
the required materials. Additionally, only 36 FDA-approved antiviral drugs were used in 
this study. However, this is perceived to be acceptable as the main focus of the presented 
work was to provide evidence for the repurposing of the currently approved antivirals in 
the treatment of COVID-19. In the future, in vitro bioassay will be conducted for the five 
captured antiviral drugs to further confirm their biological activity, and in silico screening 
of several classes of drugs and bio- and agrochemicals will be conducted using the generated 
pharmacophore.
Abbreviations, acronyms, symbols. – AIDS – Acquired Immune Deficiency Syndrome, 3CL-prote-
ase – 3C-like protease, CHARMm – Chemistry at Harvard Molecular Mechanics, COVID-19 – Corona 
Virus Disease of 2019, HBA – hydrogen bond acceptor, HBD – hydrogen bond donor, Hbic – hydro-
phobic, HIV – Human Immunodeficiency Virus, Mpro – main protease, PDB – Protein Data Bank, PLP 
– piecewise linear potential, PMF – potential mean force, RingArom – ring aromatic, RMSD – root 
mean square distance
Supplementary material available upon request.
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